Regencell Bioscience Holdings (RGC) has come under closer scrutiny after disclosing a U.S. Department of Justice subpoena into trading of its shares, with multiple shareholder class actions now challenging its past risk disclosures.

The DOJ subpoena and wave of class actions have arrived after a sharp pullback in recent weeks, with the 30 day share price return down 18.74%, even though the total shareholder return over the past year is 34.74% and the three year total shareholder return is very large.

If these legal headlines have you reassessing risk, it can help to see what else is available and compare stories using our screener of 21 top founder-led companies

So, with shares down 18.74% over the past month but still showing a 34.74% total return over one year and a very large three year gain, is Regencell now mispriced, or is the market already incorporating all the future growth?

Preferred Price-to-Book Multiple of 9,004x: Is It Justified?

On simple P/B terms, Regencell looks extremely expensive, with a Price-to-Book ratio of 9,004.3x against a last close of $22.16.

P/B compares the stock price with the accounting value of net assets. It can be a blunt tool for early stage bioscience companies that have limited tangible assets but are investing heavily in research and development. For Regencell, the combination of very small reported revenue, ongoing losses and a very large market cap of about $11.8b means most of the current valuation is tied to expectations rather than current financial performance.

Against peers, the contrast is stark. The US Pharmaceuticals peer group sits at an average P/B of 56x, and the wider US Pharmaceuticals industry average is 2.1x, while Regencell trades at 9,004.3x. That kind of gap suggests the market is assigning a very large premium relative to both peers and the sector, which investors may want to examine closely alongside the company’s risk profile and legal developments.

Result: Price-to-Book of 9,004.3x (OVERVALUED)

However, the DOJ subpoena, class actions and current lack of reported revenue all sit in the background as potential brakes on the bullish narrative.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If all of this sounds intense, that is because the risk conversation around Regencell has clearly heated up. It makes sense to review the facts for yourself and move quickly to shape your own view, starting with the company's 3 important warning signs

Looking for more investment ideas?

Do not stop at one stock. Use the screener to scan fresh opportunities now, so you do not miss ideas that better fit your goals.

• Target strong potential upside by reviewing 24 elite penny stocks with strong financials, which combine smaller size with focused business models and room for expansion.
• Prioritise quality at a sensible price by assessing 47 high quality undervalued stocks, which pair solid fundamentals with pricing that may appeal to value focused investors.
• Seek steadier portfolio anchors by checking 65 resilient stocks with low risk scores, which show lower risk scores compared with many other stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.